Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, novembre 18
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Scienture Holdings Inc
SCNX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$2.76
-0.23
-7.69%
À la clôture: Nov 17, 4:00 PM EST
$2.93
0.17
6.16%
Après les heures: 9:02 AM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Dividendes
Comparer
Rapport sur les stocks
Résultats:
Les résultats Q3 2026 ont été publiés le lun. nov. 16th, avant l'ouverture du marché
Scienture Holdings Financials
Scienture Holdings (SCNX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Scienture Holdings Q3 EPS $(3.76) Misses $(1.57) Estimate, Sales $1.255M Beat $1.220M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(3.76) per share which missed the analyst consensus estimate of $(1.57) by 139.49 percent. This is a 21.01 percent increase over losses of $(4.76) per share
Benzinga Newsdesk
PRO
Scienture Holdings Reports Preliminary Q3 Revenue Growth To $1.22M; Co Targeting Profitability In 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™Two FDA-Approved Commercial Products
Benzinga Newsdesk
PRO
SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers
Benzinga Newsdesk
PRO
EXCLUSIVE: Scienture Reports Preliminary Q3 Sales of ~$1.22M, Sequential Growth of 256%, Arbli Wholesale Unit Sales Increased 74% Sequentially
Benzinga Newsdesk
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.
Vandana Singh
PRO
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 85.42 percent increase over losses of $(0.48) per share
Benzinga Newsdesk